Welcome!

News Feed Item

Kymab Announces Publication of the Kymouse Technology in Nature Biotechnology

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ --



Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature  Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse™ (http://dx.doi.org/).

Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this new technology Kymouse™.  They have demonstrated that these mice develop an enormous range of human antibodies which can be developed as potent drugs to treat a variety of human diseases such as cancer, autoimmune and infectious diseases.

Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate all its attributes.

Professor  Allan  Bradley,  Founder  and  Chief  Scientific  Officer  of  Kymab,  said:  "This  is  a  remarkable  achievement  in  our  journey  towards  delivering  therapeutic  antibodies  and  to  facilitate  vaccine  development.  Kymab  scientists  have  completed  the  most  ambitious  humanization  project  of  the  mouse  genome  ever  undertaken,  with  5.4  million  bases  of  human  DNA,  representing  0.1%  of  the  human  genome  inserted  into  the  appropriate  place  in  the  mouse  genome."  

Dr  Christian  Grøndahl,  Chief  Executive  Officer  of  Kymab,  added:  "We  are  delighted  to  publish  our  technology  in  this  highly  prestigious  journal  and  to  present  the  first  professional  peer-reviewed  publication  of  transgenic  mice  with  a  fully  human  antibody  repertoire.  Antibodies  discovered  using  Kymouse™  strains  are  essentially  ready  to  be  developed  as  drugs.  We  are  building  a  rich  pipeline  of  first-in-class  therapeutics  in  five  areas:  haematology,  oncology,  auto-immunity,  pain  and  cardiovascular  disease.  This  technology  offers  great  potential  to  advance  patient  care  in  diseases  with  significant  unmet  medical  need."

Dr  David  Chiswell,  former  CEO  of  Cambridge  Antibody  Technology  and  Chairman  of  Kymab's  Board  of  Directors  said:  "Kymab's  highly  innovative  and  technically  advanced  Kymouse™  platform  has  overcome  the  problems  which  limited  previous  generations  of  human  antibody  generating  mice  and  is  a  strong  foundation  on  which  we  can  build  a  global  biotechnology  company."

Mice with portions of the human antibody repertoire have been developed previously. However, the technology used at the time proved unsuitable for moving the very large stretches of DNA from the human genome into the mouse. As a result their antibody gene repertoires were both incomplete and in the wrong location in the genome. Kymab scientists took a different approach and moved these vast stretches of DNA into the mouse genome in a series of steps each with a smaller segment of DNA, carefully re-joining them and thereby re-constructing the complete human repertoire in the correct place in the mouse genome.

By using the Kymouse™ technology, Kymab can pursue the targeting of the most challenging drug targets ranging from complicated ion channels and GPCRs to deeply hidden epitopes in heavily glycosylated virus proteins.

To make these sophisticated resources widely available, Kymab has created Kymab Access, a programme that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics by partnering with Kymab and its world leading Kymouse™ antibody technology.

About  Kymab 

Kymab is a biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ transgenic antibody platform.

Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding that rare drug candidate with best-in-class characteristics. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. The first Kymouse™ antibody discovery agreement was concluded with Novo Nordisk in 2013.

Founded in 2009, Kymab raised £20m of equity financing in 2010 from the investment division of the Wellcome Trust. It has an experienced management team with a successful track record in drug discovery and development and has seven current therapeutic antibody discovery programmes in immune-oncology, auto-immunity, haematology, chronic pain and cardiovascular diseases.

About  Kymab  Access 

Kymab is committed, with the support of its primary investor, The Wellcome Trust, to collaborate with leading academic experts. Kymab Access is a programme that enables academic researchers to pursue the discovery and development of novel human monoclonal antibody therapeutics by partnering researchers with Kymab and its world leading Kymouse™ antibody technology. Kymab Access is administered by Kymab Access Limited, which is a wholly owned subsidiary of Kymab established solely for this purpose with a confidentiality firewall between its operations and those of Kymab.

For further information, please visit http://www.kymab.com and http://www.kymabaccess.org

About  Wellcome  Trust  Sanger  Institute 

The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.

http://www.sanger.ac.uk/

About  Wellcome  Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

http://www.wellcome.ac.uk/

Contact  Kymab: 
Dr Christian Grøndahl, Chief Executive Officer
Tel: +44-1223-833301, Email: [email protected]

Hume  Brophy
Mary Clark, Hollie Vile and Supriya Mathur
Tel: +44(0)20-3440-5653, Email: [email protected]

Kymab,  Kymouse,  Kymab  Access  are  trademarks  of  Kymab  Limited.

SOURCE Kymab

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
For better or worse, DevOps has gone mainstream. All doubt was removed when IBM and HP threw up their respective DevOps microsites. Where are we on the hype cycle? It's hard to say for sure but there's a feeling we're heading for the "Peak of Inflated Expectations." What does this mean for the enterprise? Should they avoid DevOps? Definitely not. Should they be cautious though? Absolutely. The truth is that DevOps and the enterprise are at best strange bedfellows. The movement has its roots in t...
DXWorldEXPO LLC, the producer of the world's most influential technology conferences and trade shows has announced the 22nd International CloudEXPO | DXWorldEXPO "Early Bird Registration" is now open. Register for Full Conference "Gold Pass" ▸ Here (Expo Hall ▸ Here)
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
In their session at @DevOpsSummit at 21st Cloud Expo, Michael Berman, VP Engineering at TidalScale, and Ivo Jimenez, Engineer at TidalScale, will describe how automating tests in TidalScale is easy thanks to WaveRunner. They will show how they use WaveRunner, Jenkins, and Docker to have agile delivery of TidalScale. Michael Berman is VP Engineering at TidalScale. TidalScale is developing a scale up compute and resource architecture for customers to perform big data exploration and real time anal...
I think DevOps is now a rambunctious teenager - it's starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The “Digital Era” is forcing us to engage with new methods to build, operate and maintain applications. This transformation also implies an evolution to more and more intelligent applications to better engage with the customers, while creating significant market differentiators. In both cases, the cloud has become a key enabler to embrace this digital revolution. So, moving to the cloud is no longer the question; the new questions are HOW and WHEN. To make this equation even more complex, most ...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...